


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



wherein

R<sup>1</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

X represents -N(H)Y<sup>1</sup>, -N(H)-C<sub>1-6</sub> alkyleneY<sup>1</sup>, biphenyl or C<sub>1-6</sub> alkyl substituted by biphenyl;

wherein

said biphenyl is substituted by Z<sup>1</sup>, Z<sup>2</sup> and or Z<sup>3</sup>;

Y<sup>1</sup> represents biphenyl substituted by Z<sup>3</sup>, Z<sup>4</sup> and or Z<sup>5</sup>;

Z<sup>1</sup> and Z<sup>2</sup> are identical or different and represent hydrogen, halogen, carboxy, nitro, C<sub>1-6</sub> alkyl optionally substituted by cyano or mono-,

di-, or tri- halogen, C<sub>1-6</sub> alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkylthio, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkanoyl, or C<sub>1-6</sub> alkoxycarbonyl;

Z<sup>3</sup> represents hydrogen, halogen, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri- halogen, or C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri- halogen;

Z<sup>4</sup> represents halogen, carboxy, nitro, C<sub>1-6</sub> alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkylthio, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkanoyl, or C<sub>1-6</sub> alkoxycarbonyl; and

Z<sup>5</sup> represents hydrogen, halogen, carboxy, nitro, C<sub>1-6</sub> alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkylthio, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkanoyl, or C<sub>1-6</sub> alkoxycarbonyl;

or

Z<sup>4</sup> and Z<sup>5</sup> together with the carbon atom to which they are attached, form a benzene ring.


2. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

$R^1$  represents hydrogen;

X represents  $-N(H)Y^1$  or  $-N(H)-C_{1-6}$  alkylene  $Y^1$ ;

$Y^1$  represents



$Z^3$  represents hydrogen, fluoro, chloro, bromo, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino,  $C_{1-6}$  alkoxy optionally substituted by cyano or mono-, di-, or tri- halogen, or  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen;

$Z^4$  represents halogen, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, amino,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl; and

$Z^5$  represents hydrogen, halogen, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy

optionally substituted by morpholino, or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkylthio, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkanoyl, or C<sub>1-6</sub> alkoxy carbonyl.


3. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R<sup>1</sup> represents hydrogen;

X represents -N(H)Y<sup>1</sup> or -N(H)-C<sub>1-6</sub> alkylene Y<sup>1</sup>;

Y<sup>1</sup> represents



Z<sup>3</sup> represents hydrogen or piperidino;

Z<sup>4</sup> represents fluoro, chloro, bromo, carboxy, nitro, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri- halogen, C<sub>1-6</sub> alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkylthio, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkanoyl, or C<sub>1-6</sub> alkoxy carbonyl; and


$Z^5$  represents hydrogen, fluoro, chloro, bromo,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio or  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen.

4. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

$R^1$  represents hydrogen;

X represents



$n$  represents an integer selected from 0 to 6;


$Z^1$  and  $Z^2$  are identical or different and represent hydrogen, fluoro, chloro, bromo, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl; and

$Z^3$  represents hydrogen, fluoro, chloro, bromo, amino, piperidino,  $C_{1-6}$  alkoxy optionally substituted by mono-, di-, or tri- halogen, or  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen.

5. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein

$R^1$  represents hydrogen;

X represents



n represents an integer of 0 or 1;

$Z^1$  represents hydrogen, fluoro, chloro, bromo,  $C_{1-6}$ alkyl,  $C_{1-6}$  alkoxy, amino,  $C_{1-6}$  alkylamino, or di( $C_{1-6}$  alkyl)amino;

$Z^2$  represents hydrogen, fluoro, chloro, bromo,  $C_{1-6}$  alkyl or  $C_{1-6}$  alkoxy; and

$Z^3$  represents hydrogen.

6. (Currently amended) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said tetrahydro-naphthalenyl derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'-(trifluoromethyl)-biphenyl-3-yl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[2'-(trifluoromethyl)-biphenyl-3-yl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'-(methylthio)-biphenyl-3-yl]urea;

N-(2',3'-dichlorobiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(2',4'-dichlorobiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(4'-acetylbiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

~~N-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;~~

N-[(2',6'-difluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(2'-fluorobiphenyl-3-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[(4'-isopropylbiphenyl-3-yl)methyl]urea; and

N-[(2',4'-dichlorobiphenyl-3-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea.

7. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising a tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 ~~in~~ as an active ingredient, plus a pharmaceutically acceptable carrier.

8. (Cancelled)
9. (Currently amended) The ~~medicament~~ pharmaceutical composition as claimed in claim 7, wherein said tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
10. (Cancelled)
11. (Cancelled)
12. (Cancelled).
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)



21. (Currently amended) ~~Process~~ A process for controlling ~~an~~ a urological disorder or disease in humans and animals ~~by administration of~~ comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.
22. (Currently amended) ~~Process~~ A process for controlling pain in humans and animals ~~by administration of~~ comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.
23. (Currently amended) ~~Process~~ A process for controlling an inflammatory disorder or disease in humans and animals ~~by administration of~~ comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.
24. (New) A method for treatment and/or prophylaxis of a urological disorder in a human or animal, said urological disorder being selected from urinary incontinence, overactive bladder, and urge urinary incontinence, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.
25. (New) A method for treatment and/or control of a painful condition in a human or animal, said painful condition being selected from chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia,, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, and stroke, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.
26. (New) A method for treatment and/or prophylaxis of an inflammatory disorder in a human or animal, said inflammatory disorder being selected from asthma and COPD, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.